Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
31
KPRX Quote, Financials, Valuation and Earnings
Last price:
$2.05
Seasonality move
:
-5.21%
Day range:
$2.05 - $2.10
52-week range:
$1.76 - $4.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.34x
Volume:
29.6K
Avg. volume:
66.5K
1-year change:
-41.31%
Market cap:
$7.6M
Revenue:
$16M
EPS (TTM):
-$2.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KPRX
Kiora Pharmaceuticals, Inc.
|
$1.5M | -$0.70 | 3650% | -11.09% | $11.00 |
|
ABEO
Abeona Therapeutics, Inc.
|
$5.6M | -$0.34 | -97.62% | -57.23% | $20.64 |
|
ATOS
Atossa Therapeutics, Inc.
|
-- | -$1.14 | -- | -1919.23% | $80.00 |
|
CLCS
Cell Source, Inc.
|
-- | -- | -- | -- | -- |
|
CLDX
Celldex Therapeutics, Inc.
|
$1.5M | -$1.00 | -9.83% | -30.49% | $53.36 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KPRX
Kiora Pharmaceuticals, Inc.
|
$2.06 | $11.00 | $7.6M | -- | $0.00 | 0% | -- |
|
ABEO
Abeona Therapeutics, Inc.
|
$5.29 | $20.64 | $286.7M | 4.54x | $0.00 | 0% | 715.16x |
|
ATOS
Atossa Therapeutics, Inc.
|
$4.42 | $80.00 | $38.1M | -- | $0.00 | 0% | -- |
|
CLCS
Cell Source, Inc.
|
$0.8500 | -- | $38.3M | -- | $0.00 | 0% | -- |
|
CLDX
Celldex Therapeutics, Inc.
|
$23.54 | $53.36 | $1.6B | -- | $0.00 | 0% | 601.06x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.29 | $5.50 | $40.2M | -- | $0.00 | 0% | 4.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KPRX
Kiora Pharmaceuticals, Inc.
|
1.77% | 0.329 | 4.23% | 7.51x |
|
ABEO
Abeona Therapeutics, Inc.
|
12.34% | -1.035 | 8.71% | 9.35x |
|
ATOS
Atossa Therapeutics, Inc.
|
-- | 0.662 | -- | 6.32x |
|
CLCS
Cell Source, Inc.
|
-- | -0.372 | -- | -- |
|
CLDX
Celldex Therapeutics, Inc.
|
0.44% | 1.179 | 0.15% | 12.42x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KPRX
Kiora Pharmaceuticals, Inc.
|
-$38.2K | -$2.5M | -34.13% | -34.44% | 82.56% | -$1.3M |
|
ABEO
Abeona Therapeutics, Inc.
|
-$1.4M | -$24M | 70.47% | 88.36% | -5698% | -$23.7M |
|
ATOS
Atossa Therapeutics, Inc.
|
-$4K | -$9.3M | -47.46% | -47.46% | -- | -$6M |
|
CLCS
Cell Source, Inc.
|
-- | -$831.6K | -- | -- | -- | -$639K |
|
CLDX
Celldex Therapeutics, Inc.
|
-$824K | -$73.6M | -32.02% | -32.17% | -8747.53% | -$49.1M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Kiora Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns KPRX or ABEO?
Abeona Therapeutics, Inc. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of --. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Abeona Therapeutics, Inc.'s return on equity of 88.36%.
Company Gross Margin Earnings Per Share Invested Capital KPRXKiora Pharmaceuticals, Inc.-- $0.01 $22.8M ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M -
What do Analysts Say About KPRX or ABEO?
Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 433.98%. On the other hand Abeona Therapeutics, Inc. has an analysts' consensus of $20.64 which suggests that it could grow by 290.22%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Abeona Therapeutics, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Abeona Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KPRXKiora Pharmaceuticals, Inc.0 0 0 ABEOAbeona Therapeutics, Inc.6 0 0 -
Is KPRX or ABEO More Risky?
Kiora Pharmaceuticals, Inc. has a beta of -0.819, which suggesting that the stock is 181.948% less volatile than S&P 500. In comparison Abeona Therapeutics, Inc. has a beta of 1.175, suggesting its more volatile than the S&P 500 by 17.515%.
-
Which is a Better Dividend Stock KPRX or ABEO?
Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abeona Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Abeona Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KPRX or ABEO?
Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Abeona Therapeutics, Inc. quarterly revenues of --. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is higher than Abeona Therapeutics, Inc.'s net income of -$5.2M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Abeona Therapeutics, Inc.'s PE ratio is 4.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus 715.16x for Abeona Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KPRXKiora Pharmaceuticals, Inc.-- -- -- $26.8K ABEOAbeona Therapeutics, Inc.715.16x 4.54x -- -$5.2M
-
Which has Higher Returns KPRX or ATOS?
Atossa Therapeutics, Inc. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of --. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Atossa Therapeutics, Inc.'s return on equity of -47.46%.
Company Gross Margin Earnings Per Share Invested Capital KPRXKiora Pharmaceuticals, Inc.-- $0.01 $22.8M ATOSAtossa Therapeutics, Inc.-- -$0.07 $49.8M -
What do Analysts Say About KPRX or ATOS?
Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 433.98%. On the other hand Atossa Therapeutics, Inc. has an analysts' consensus of $80.00 which suggests that it could grow by 1455.43%. Given that Atossa Therapeutics, Inc. has higher upside potential than Kiora Pharmaceuticals, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Kiora Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KPRXKiora Pharmaceuticals, Inc.0 0 0 ATOSAtossa Therapeutics, Inc.3 0 0 -
Is KPRX or ATOS More Risky?
Kiora Pharmaceuticals, Inc. has a beta of -0.819, which suggesting that the stock is 181.948% less volatile than S&P 500. In comparison Atossa Therapeutics, Inc. has a beta of 1.364, suggesting its more volatile than the S&P 500 by 36.379%.
-
Which is a Better Dividend Stock KPRX or ATOS?
Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atossa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Atossa Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KPRX or ATOS?
Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Atossa Therapeutics, Inc. quarterly revenues of --. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is higher than Atossa Therapeutics, Inc.'s net income of -$8.7M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Atossa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus -- for Atossa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KPRXKiora Pharmaceuticals, Inc.-- -- -- $26.8K ATOSAtossa Therapeutics, Inc.-- -- -- -$8.7M
-
Which has Higher Returns KPRX or CLCS?
Cell Source, Inc. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of --. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Cell Source, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KPRXKiora Pharmaceuticals, Inc.-- $0.01 $22.8M CLCSCell Source, Inc.-- -$0.04 -- -
What do Analysts Say About KPRX or CLCS?
Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 433.98%. On the other hand Cell Source, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Cell Source, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Cell Source, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KPRXKiora Pharmaceuticals, Inc.0 0 0 CLCSCell Source, Inc.0 0 0 -
Is KPRX or CLCS More Risky?
Kiora Pharmaceuticals, Inc. has a beta of -0.819, which suggesting that the stock is 181.948% less volatile than S&P 500. In comparison Cell Source, Inc. has a beta of -225.097, suggesting its less volatile than the S&P 500 by 22609.671%.
-
Which is a Better Dividend Stock KPRX or CLCS?
Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cell Source, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cell Source, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KPRX or CLCS?
Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are larger than Cell Source, Inc. quarterly revenues of --. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is higher than Cell Source, Inc.'s net income of -$1.4M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cell Source, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus -- for Cell Source, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KPRXKiora Pharmaceuticals, Inc.-- -- -- $26.8K CLCSCell Source, Inc.-- -- -- -$1.4M
-
Which has Higher Returns KPRX or CLDX?
Celldex Therapeutics, Inc. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of -7753.43%. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.
Company Gross Margin Earnings Per Share Invested Capital KPRXKiora Pharmaceuticals, Inc.-- $0.01 $22.8M CLDXCelldex Therapeutics, Inc.-19.59% -$1.01 $601M -
What do Analysts Say About KPRX or CLDX?
Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 433.98%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.36 which suggests that it could grow by 126.67%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Celldex Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KPRXKiora Pharmaceuticals, Inc.0 0 0 CLDXCelldex Therapeutics, Inc.12 2 0 -
Is KPRX or CLDX More Risky?
Kiora Pharmaceuticals, Inc. has a beta of -0.819, which suggesting that the stock is 181.948% less volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.242, suggesting its more volatile than the S&P 500 by 24.184%.
-
Which is a Better Dividend Stock KPRX or CLDX?
Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KPRX or CLDX?
Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Celldex Therapeutics, Inc. quarterly revenues of --. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus 601.06x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KPRXKiora Pharmaceuticals, Inc.-- -- -- $26.8K CLDXCelldex Therapeutics, Inc.601.06x -- -- -$67M
-
Which has Higher Returns KPRX or PSTV?
Plus Therapeutics, Inc. has a net margin of 84.08% compared to Kiora Pharmaceuticals, Inc.'s net margin of -316.61%. Kiora Pharmaceuticals, Inc.'s return on equity of -34.44% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KPRXKiora Pharmaceuticals, Inc.-- $0.01 $22.8M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About KPRX or PSTV?
Kiora Pharmaceuticals, Inc. has a consensus price target of $11.00, signalling upside risk potential of 433.98%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1778.42%. Given that Plus Therapeutics, Inc. has higher upside potential than Kiora Pharmaceuticals, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Kiora Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KPRXKiora Pharmaceuticals, Inc.0 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is KPRX or PSTV More Risky?
Kiora Pharmaceuticals, Inc. has a beta of -0.819, which suggesting that the stock is 181.948% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock KPRX or PSTV?
Kiora Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiora Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KPRX or PSTV?
Kiora Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Kiora Pharmaceuticals, Inc.'s net income of $26.8K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Kiora Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiora Pharmaceuticals, Inc. is -- versus 4.69x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KPRXKiora Pharmaceuticals, Inc.-- -- -- $26.8K PSTVPlus Therapeutics, Inc.4.69x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 2.23% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 0.38% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is up 0.8% over the past day.
